tirzepatide clinical trial weight loss results surmount-1 Analysis of Acquisition Costs and Reduction Outcomes in the United Kingdom: Insights from the Study How Tirzepatide Helped A 24

44 Current research on the potential of GLP-1RAs in the management of HS is limited

The most common side effects include nausea, vomiting, diarrhoea, decreased appetite, constipation, stomach pain, and indigestion, and these tend to be most noticeable during the initial weeks of treatment or shortly after a dose increase, typically easing as the body adjusts

Tirzepatides dual GIP receptor engagement produces 2030% more weight loss over 68 weeks in clinical trials

Iwasaki, Y., Sendo, M., Dezaki, K., Hira, T., Sato, T., Nakata, M., Goswami, C., Aoki, R., Arai, T., Kumari, P., Hayakawa, M., Masuda, C., Okada, T., Hara, H., Drucker, D

ZEPBOUND has not been studied in patients with severe gastrointestinal disease, including severe gastroparesis, and is therefore not recommended in these patients